# Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

> **NCT03781960** · PHASE2 · TERMINATED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 7 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03781960
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-31
- **Primary completion:** 2022-04-29
- **Final completion:** 2022-04-29
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Safety letter from sponsor
- **Last updated:** 2022-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03781960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03781960, "Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03781960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*